TNF-alpha blocker treatment for enterocolitis associated with immunostimulatory therapeutic antibody therapy
AssigneeMedarex, Inc.
InventorsSteven Fischkoff, Israel Lowy, Michael Yellin, James Chung-Yin Yang
Life of this patent
Estimating the term…
Abstract
The present invention provides methods for treating adverse events related to immunotherapy. More specifically, the present invention provides methods for treating the enterocolitis associated with anti-CTLA-4 antibody immunotherapy.
Claims20
A method for treating enterocolitis induced by an-anti-CTLA-4 antibody in a patient, comprising administering to the patient an amount of a TNF-α blocking agent effective to treat the enterocolitis, wherein the TNF-α blocking agent is selected from the group consisting of an anti-TNF-α antibody and a TNF receptor fusion protein.
A method for treating enterocolitis induced by an-anti-CTLA-4 antibody in a patient, comprising administering to the patient an amount of a TNF-α blocking agent effective to treat the enterocolitis, wherein the TNF-α blocking agent is selected from the group consisting of an anti-TNF-α antibody and a TNF receptor fusion protein, wherein the enterocolitis induced by an anti-CTLA-4 antibody is refractory to steroid treatment.
Dependencies are inferred from the claim text.